Table 1 Sociodemographic and Clinical Characteristics (n = 220)
At the start of ChEI treatment | At nursing-home placementa | |
|---|---|---|
Variable | n/% | n/% |
Female sex | 161/73 % | na |
APOE genotype, (n = 208) | na | |
No ε4 alleles | 57/27 % | |
One ε4 allele | 118/57 % | |
Two ε4 alleles | 33/16 % | |
Solitary living | 116/53 % | 126/57 % |
Antihypertensive/cardiac therapy | 79/36 % | |
Antidiabetics | 9/4 % | |
Asthma medication | 9/4 % | |
Thyroid therapy | 19/9 % | |
Lipid-lowering agents | 15/7 % | |
Estrogens | 17/8 % | |
NSAIDs/acetylsalicylic acid | 63/29 % | |
Antidepressants | 71/32 % | |
Antipsychotics | 14/6 % | |
Anxiolytics/sedatives/hypnotics | 41/19 % | |
Variable | Mean ± standard deviation | |
Estimated age at onset of AD, years | 73.5 ± 6.9 | na |
Estimated duration of AD, years | 3.4 ± 2.6 | 5.1 ± 2.7 |
Age, years | 76.9 ± 5.9 | 78.6 ± 5.8 |
Education, years | 9.2 ± 2.3 | na |
MMSE score | 20.1 ± 4.0 | 17.5 ± 5.7 |
ADAS-cog score (0–70) | 24.0 ± 9.7 | 29.2 ± 12.5 |
IADL score | 18.3 ± 5.1 | 22.7 ± 4.7 |
PSMS score | 8.2 ± 2.8 | 10.5 ± 3.9 |
Number of concomitant medicationsa | 3.0 ± 2.4 | |
Home-help service, h/week | 6.6 ± 5.4 (n = 56) | 5.7 ± 6.5 (n = 180) |
Adult day care, days/week | 3.2 ± 1.7 (n = 23) | 3.0 ± 1.4 (n = 82) |
Mean dose of ChEI during the SATS, mg | ||
Donepezil (n = 138) | 6.8 ± 1.8 | na |
Rivastigmine (n = 37) | 5.7 ± 1.9 | na |
Galantamine (n = 45) | 15.1 ± 3.2 | na |
Time to nursing home placement from the start of ChEI therapy, months | 19.5 ± 10.0 | na |
Age at death, years | 82.6 ± 6.0 | na |